Targeting the MYCN–PARP–DNA Damage Response Pathway in Neuroendocrine Prostate Cancer
Yaoguang Zhang(Beijing United Family Hospital), Timothy C. Thompson(The University of Texas MD Anderson Cancer Center), Spyridon P. Basourakos(Mayo Clinic in Arizona), Ana M. Aparicio(The University of Texas MD Anderson Cancer Center), Yang Luan(Tongji Hospital), Jeri Kim(The University of Texas MD Anderson Cancer Center), Xuhong Cao(Howard Hughes Medical Institute), Nora M. Navone(The University of Texas MD Anderson Cancer Center), Dimitrios Korentzelos(University of Pittsburgh Medical Center), Patricia Troncoso(The University of Texas MD Anderson Cancer Center), Paul G. Corn(Cornell University), Guang Yang(Jinan University), Jianxiang Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Liu(Union Hospital), Sanghee Park(Hanbat National University), Abul Kalam Azad(The University of Texas MD Anderson Cancer Center), Wenhui Wu(The University of Texas MD Anderson Cancer Center), Likun Li(The University of Texas MD Anderson Cancer Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Arul M. Chinnaiyan(Howard Hughes Medical Institute), Bradley M. Broom(The University of Texas MD Anderson Cancer Center)
Cited by 108
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
The Molecular Taxonomy of Primary Prostate Cancer
|Cell|2015|3.3k